

1 **Title: Risk of tuberculosis and uptake rates of latent tuberculosis infection screening among**
2 **clinical risk groups in South Korea: A nationwide population-based cohort study**

3

4 **Short title: Risk of TB and LTBI screening among clinical risk groups in Korea**

5

6 **Authors:** Hyung Woo Kim¹, Jinsoo Min², Joon Young Choi¹, Ah Young Shin¹, Jun-Pyo Myong³,
7 Yunhee Lee³, Hyeon Woo Yim⁴, Hyunsuk Jeong⁴, Sanghyuk Bae⁴, Choi Hoyong⁵, Hyekyung In⁵,
8 Ahyoung Park⁵, Miri Jang⁵, Hyeon-Kyoung Koo⁶, Sung-Soon Lee⁶, Jae Seuk Park⁷, Ju Sang Kim^{1*}

9

10 **Affiliations:**

11 ¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St.
12 Mary's Hospital, College of Medicine, The Catholic University of Korea

13 ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's
14 Hospital, College of Medicine, The Catholic University of Korea,

15 ³Department of Occupational and Environmental Medicine, Seoul St. Mary's Hospital, College of
16 Medicine, The Catholic University of Korea,

17 ⁴Department of Preventive Medicine, College of Medicine, The Catholic University of Korea,

18 ⁵Division of Tuberculosis Prevention and Control, Korea Disease Control and Prevention Agency,

19 ⁶Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik
20 Hospital, Inje University College of Medicine,

21 ⁷Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook
22 University College of Medicine

23

24 *** Correspondence:**

25 Ju Sang Kim

26 kimjusang@catholic.ac.kr

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Abstract**

29 **Background:** This study aimed to investigate actual tuberculosis (TB) risk and uptake rates of latent
30 tuberculosis infection (LTBI) screening among eight clinical risk groups specified in Korean
31 guidelines. Proportions of potentially preventable TB in these groups were also calculated.

32 **Methods and Findings:** Patients enrolled before January 1st, 2018, were classified into a prevalence
33 cohort whereas those enrolled thereafter were classified into an incidence cohort. Both cohorts were
34 followed up until December 31st, 2020. Sex, age, and calendar year-adjusted standardized incidence
35 ratio (SIR) of tuberculosis was calculated with total population in South Korea as a reference group.
36 The number of TB patients notified in 2018 was investigated for both prevalence and incidence
37 cohorts. SIR of TB in each incidence cohort was higher than that in each corresponding prevalence
38 cohort. Among all incidence cohorts, SIR in people living with human immunodeficiency virus
39 (PLHIV) was the highest (17.41, (95% CI: 14.14-21.43)). Although classified as moderate TB risk
40 diseases in current guideline, end-stage renal disease (ESRD) (8.05, (7.02-9.23)) and uncontrolled
41 diabetes mellitus (DM) (6.31, (5.78-6.99)) showed high SIRs comparable to other high-risk diseases.
42 Among total TB cases notified in 2018, each cohort accounted for less than 1.5% except for patients
43 with DM. The uptake rate of LTBI test was the highest among patients using TNF inhibitors (92.7%),
44 followed by those who underwent organ transplantation (60.4%) and PLHIV (41.3%).

45 **Conclusions:** LTBI screening should be reinforced for certain clinical risk groups such as ESRD or
46 uncontrolled DM. Beyond the current guideline, additional high-risk groups should be identified.

47

48 **Keywords:** Tuberculosis; Incidence; Latent tuberculosis; Relative Risk; Screening

49 INTRODUCTION

50 Approximately a quarter of population in the world is presumed to be infected with
51 tuberculosis (TB)[1]. For TB elimination, strategies to tackle the large TB reservoir are essential[2].
52 However, current diagnostic tools for latent tuberculosis infection (LTBI) have low predictive
53 values[3], which can result in high numbers needed treat to prevent a TB case. Several conditions
54 raising TB risk have been investigated[4]. Previous guidelines on LTBI have commonly specified two
55 key groups: TB contacts and clinical risk groups[5-8].

56 TB incidence in South Korea has continuously decreased since 2000. TB incidence was 96.3
57 cases per 100,000 population in 2000 and 44.6 cases per 100,000 population in 2021[9]. With a
58 decrease in TB incidence, strategy to prevent reactivation has been underscored as in other low-
59 incidence countries[10,11]. However, in contrast to contact investigation which is managed by the
60 government[12], LTBI screening in clinical risk group is usually performed in private sector, which
61 accounts for more than 90% healthcare facilities in South Korea[13]. Although clinical risk groups
62 have been specified in Korean guidelines since amendment in 2014[14], actual TB risk and uptake
63 rate of LTBI screening in these groups have not been evaluated before.

64 Thus, the objective of this study was to investigate the actual TB risk among high-risk
65 groups specified in Korean guidelines for TB and uptake rate of LTBI screening in each group.
66 Additionally, proportions of potentially preventable TB by implementing LTBI screening in these risk
67 groups were calculated among total nationwide TB burden.

68

69 METHODS

70 Study population and data source

71 Eight diseases specified in Korean guidelines were selected. Records of patients with such
72 disease were extracted from National Health Information Database (NHID) according to the
73 operational definition of each disease (S1 Table). Each group was denoted as follows: Group 1,
74 people living with human immunodeficiency virus (PLHIV); Group 2, patients who underwent solid
75 organ or hematopoietic stem cell transplantation; Group 3, patients who used tumor necrosis factor

76 (TNF) inhibitors; Group 4, patients with end-stage renal disease (ESRD); Group 5, patients who
77 underwent gastrectomy; Group 6, patients with head & neck cancer; Group 7, patients with
78 hematologic malignancy; and Group 8, patients with diabetes mellitus (DM). Additionally, in Group
79 8, patients who needed regular insulin injection implying patients with poorly controlled DM were
80 selected and analyzed as Group 8-1. Three diseases (Group 1, Group 2, and Group 3) were classified
81 as high-risk diseases while others were classified as moderate-risk diseases. The date of enrollment
82 was defined as the first date that criteria for operational definition were all met. Patients enrolled
83 before January 1st, 2018 were classified into a prevalence cohort, representing patients who had the
84 disease at the timepoint of January 1st, 2018. Those enrolled on 1st January 2018 or thereafter were
85 classified into an incidence cohort, who were newly diagnosed patients. Patients died before January
86 1st, 2018 were excluded. Patients with missing information on demographic variables such as age and
87 sex were also excluded. Each cohort was linked to database of Korean National TB Surveillance
88 System (KNTSS) using national identification number.

89

90 **Study design**

91 Patients enrolled in each cohort were followed up from January 1st, 2018 for the prevalence
92 cohort and from the date of enrollment for the incidence cohort. Follow-up was terminated at 1) date
93 of TB diagnosis, 2) date of death or 3) 31st December 2020, whichever came first. Incidence rate of
94 TB and mortality were calculated for each cohort. To estimate TB risk, sex, age, and calendar year-
95 adjusted standardized incidence ratio (SIR) of tuberculosis were calculated with total population in
96 South Korea as a reference group. TB incidence among total population was calculated using database
97 of KNTSS notified from 2018 to 2020. SIR was presented after stratifying subjects into three age
98 groups - patients aged under 35 years, those aged between 35-64 years and those aged 65 years or
99 over.

100 Age-stratified proportion of each prevalence and incidence cohort among nationwide TB
101 patients notified in 2018 was calculated. For the incidence cohort, only patients enrolled in 2018 were
102 analyzed.

103 The percentage of those who underwent interferon-gamma release assay (IGRA) or
104 tuberculin skin test (TST) was investigated. Screening was classified by the date of LTBI
105 examination. Recent screening denoted that the screening was performed within one year before the
106 date of enrollment. New screening indicated that the screening was performed at the date of
107 enrollment or thereafter. Past screening represented that the screening was performed more than one
108 year before the date of enrollment. As some patients such as those who were scheduled for organ
109 transplantation and those who were going to use TNF inhibitors were requested to undergo LTBI
110 screening in advance, the percentage of recent or new screening was presented as one of the major
111 outcomes of this analysis.

112

113 **Statistical analysis**

114 SIR based on Poisson model with 95% confidence interval from Wald's normal
115 approximation was calculated using R package 'popEpi'. All statistical analyses were conducted with
116 R v.3.6.2 (R foundation for Statistical Computing, Vienna, Austria) and SAS software version 9.4
117 (SAS Institute Inc., Cary, NC, USA). Statistical significance was considered when two-sided *P*-value
118 was less than 0.05.

119

120 **Ethics statement**


121 The present study protocol was reviewed and approved by the Institutional Review Board
122 (IRB) of Incheon St. Mary's Hospital, the Catholic University of Korea (IRB No. OC20ZNDE0023).
123 Korea Disease Control and Prevention Agency collected informed consent from all notified TB
124 patients when they were enrolled according to Tuberculosis Prevention Act. Informed consent from
125 enrolled patients with high or moderate TB risk disease was waived due to the retrospective nature of
126 this study. All enrolled patients were anonymized.

127

128 **RESULTS**

129 Numbers of finally included patients in prevalence and incidence cohorts are presented in
130 Figure 1. Demographic features of enrolled patients in each group were demonstrated in S2 Table.
131 Among eight prevalence cohorts, Group 4 showed the highest TB incidence (487.4 per 100,000
132 person-years) and mortality rate (9592.9 per 100,000 person-year). Similarly, among incidence
133 cohorts, TB incidence (1117.4 per 100,000 person-years) and mortality (19619.5 per 100,000 person-
134 years) were the highest in Group 4 (Table 1). In every group, TB incidence was higher in the
135 incidence cohort than in the prevalence cohort. Mortality was higher in the incidence cohort than in
136 the prevalence cohort for all groups except for Group 8.

137 Fig 1. Flow diagram.



138

139 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation;
 140 Group 3: patients who used tumor necrosis factor inhibitors; Group 4: patients with end-stage renal disease; Group
 141 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with
 142 hematologic malignancy; Group 8: patients with diabetes mellitus.

143

144 LTBI: latent tuberculosis infection.

145

146 Table 1. Incidence of TB and death during follow-up period (2018-2020) among each prevalence cohort and each incidence cohort

	Prevalence cohort				Incidence cohort			
	TB, N (Incidence per 100000 person- years)	Death, N (Incidence per 100000 person- years)	Total N	Total follow- up (person- years)	TB, N (Incidence per 100000 person- years)	Death, N (Incidence per 100000 person- years)	Total N	Total follow-up (person- years)
Group 1	106 (247.1)	360 (839.2)	14548	42898.8	89 (1068.3)	162 (1944.6)	4347	8330.8
Group 2	167 (146.1)	2794 (2444.6)	39779	114293.7	105 (518.1)	1867 (9211.7)	11456	20267.6
Group 3	135 (177.2)	385 (505.3)	25666	76188.8	75 (448.9)	88 (526.7)	8370	16706.2
Group 4	1189 (487.4)	23401 (9592.9)	94306	243940.4	206 (1117.4)	3617 (19619.5)	10977	18435.7
Group 5	1161 (249.1)	15396 (3303.1)	164081	466104	225 (338.5)	3900 (5867.3)	35364	66470.2
Group 6	241 (219.7)	5860 (5341.1)	39985	109714.8	172 (575.5)	3239 (10837.4)	17228	29887.2
Group 7	311 (153.1)	9496 (4674.9)	73550	203127.5	343 (620.5)	9341 (16897.0)	35055	55282.1
Group 8	14677 (150.8)	204247 (2098.1)	3353020	9735057.0	1587 (208.8)	12207 (1606.4)	306834	759891.6
Group 8-1	4881 (304.0)	79825 (4971.9)	580894	1605530.5	498 (571.8)	5340 (6131.4)	38136	87092.1

147 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation; Group 3: patients who used tumor necrosis factor inhibitors;
 148 Group 4: patients with end-stage renal disease; Group 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with hematologic
 149 malignancy; Group 8: patients with diabetes mellitus; Group 8-1: patients with diabetes mellitus who needed regular insulin injection.

150
 151 TB: tuberculosis.

152 *Standardized incidence ratio of TB*

153 Age-stratified SIR of TB in the prevalence cohort is presented in Table 2. Group 4 had the
154 highest SIR (3.76, 95% CI: 3.55-3.98), followed by Group 1 (3.61, 2.98-4.37), Group 3 (3.30, 2.79-
155 3.90), and Group 8-1 (2.30, 2.24-2.37). Although there were subtle differences among cohorts, SIRs
156 in elderly population were lower than those in younger population.

157 Table 2. Standardized incidence ratio of TB among each prevalence cohort stratified by age

Group	Age	Observed cases (n)	Expected cases (n)	Follow-up: person-years	SIR (95% CI)	P value
Group 1	<35	12	3.67	10573.1	3.27 (1.86-5.76)	<0.001
	35-64	69	16.85	27287.9	4.09 (3.23-5.18)	<0.001
	≥65	25	8.84	5037.8	2.83 (1.91-4.19)	<0.001
	Total	106	29.36	42898.8	3.61 (2.98-4.37)	<0.001
Group 2	<35	4	3.58	16261.9	1.12 (0.42-2.98)	0.825
	35-64	117	49.58	78988.0	2.36 (1.97-2.83)	<0.001
	≥65	46	22.67	19043.7	2.03 (1.52-2.71)	<0.001
	Total	167	75.84	114293.7	2.20 (1.89-2.56)	<0.001
Group 3	<35	33	7.01	22623.7	4.71 (3.35-6.63)	<0.001
	35-64	69	21.97	44699.8	3.14 (2.48-3.98)	<0.001
	≥65	33	11.96	8865.3	2.76 (1.96-3.88)	<0.001
	Total	135	40.93	76188.8	3.30 (2.79-3.90)	<0.001
Group 4	<35	8	2.09	6467.3	3.83 (1.91-7.66)	<0.001
	35-64	479	80.90	123332.8	5.92 (5.41-6.48)	<0.001
	≥65	702	233.13	114140.3	3.01 (2.8-3.24)	<0.001
	Total	1189	316.12	243940.4	3.76 (3.55-3.98)	<0.001
Group 5	<35	2	0.83	2647.9	2.41 (0.60-9.64)	0.213
	35-64	281	144.38	204652.1	1.95 (1.73-2.19)	<0.001
	≥65	878	555.09	258804.0	1.58 (1.48-1.69)	<0.001
	Total	1161	700.31	466104.0	1.66 (1.57-1.76)	<0.001
Group 6	<35	3	1.41	4742.3	2.13 (0.69-6.61)	0.189
	35-64	63	34.85	48128.0	1.81 (1.41-2.31)	<0.001
	≥65	175	125.59	56844.6	1.39 (1.2-1.62)	<0.001
	Total	241	161.84	109714.8	1.49 (1.31-1.69)	<0.001
Group 7	<35	10	8.12	37222.7	1.23 (0.66-2.29)	0.510
	35-64	105	56.09	95993.3	1.87 (1.55-2.27)	<0.001
	≥65	196	132.99	69911.5	1.47 (1.28-1.7)	<0.001
	Total	311	197.20	203127.5	1.58 (1.41-1.76)	<0.001
Group 8	<35	83	40.21	128813.8	2.06 (1.66-2.56)	<0.001
	35-64	4804	3246.43	4690996.8	1.48 (1.44-1.52)	<0.001
	≥65	9790	9163.04	4915246.4	1.07 (1.05-1.09)	<0.001
	Total	14677	12449.69	9735057.0	1.18 (1.16-1.20)	<0.001
Group 8-1	<35	56	17.00	58409.4	3.29 (2.54-4.28)	<0.001
	35-64	1834	475.81	706728.4	3.85 (3.68-4.04)	<0.001
	≥65	2991	1627.15	840392.6	1.84 (1.77-1.91)	<0.001
	Total	4881	2119.96	1605530.5	2.30 (2.24-2.37)	<0.001

158 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation;
 159 Group 3: patients who used tumor necrosis factor inhibitors; Group 4: patients with end-stage renal disease; Group
 160 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with
 161 hematologic malignancy; Group 8: patients with diabetes mellitus; Group 8-1: patients with diabetes mellitus who
 162 needed regular insulin injection.
 163

164 TB: tuberculosis; SIR: standardized incidence ratio.

165

166 Among all groups, SIR of TB was higher in the incidence cohort than in the prevalence
167 cohort (Table 3). Group 1 had the highest SIR (17.41, 14.14-21.43), followed by Group 3 (9.67, 7.71-
168 12.12), Group 2 (8.90, 7.35-10.77), and Group 4 (8.05, 7.02-9.23), which comprised the high-TB risk
169 group. Among other groups, Group 8-1 and Group 7 showed considerably high SIRs (6.31, 5.78-6.99
170 and 6.07, 5.46-6.75, respectively). As in the prevalence cohort, SIRs in elderly population were lower
171 than those in younger population. This generation gap in SIR was prominent in Group 1. For incident
172 Group 1, SIR was 33.43 (26.31-42.47) aged between 35 and 64 years and 1.42 (0.46-4.41) for those
173 who aged 65 years or over. Group 7 also showed such generation gap. For incident Group 7, SIR was
174 22.27 (15.75-31.49) for those aged under 35 years and 4.65 (4.03-5.36) for those aged 65 years or
175 over. However, in Group 3, such tendency was not prominent. For incident Group 3, SIRs for those
176 aged under 35 years, aged between 35 and 64 years, and aged 65 years or over were 8.91 (5.37-
177 14.78), 10.44 (7.69-14.18), and 8.84 (5.64-13.86), respectively.
178

179 Table 3. Standardized incidence ratio of TB among each incidence cohort stratified by age.

Group	Age	Observed cases (n)	Expected cases (n)	Follow-up: person-years	SIR (95% CI)	P value
Group 1	<35	19	1.00	3192.6	19.03 (12.14-29.84)	<0.001
	35-64	67	2.00	3972.8	33.43 (26.31-42.47)	<0.001
	≥65	3	2.11	1165.4	1.42 (0.46-4.41)	0.542
	Total	89	5.11	8330.8	17.41 (14.14-21.43)	<0.001
Group 2	<35	9	0.59	3109.4	15.16 (7.89-29.13)	<0.001
	35-64	77	8.75	14784.4	8.80 (7.04-11.00)	<0.001
	≥65	19	2.46	2373.8	7.73 (4.93-12.12)	<0.001
	Total	105	11.80	20267.6	8.90 (7.35-10.77)	<0.001
Group 3	<35	15	1.68	6557.5	8.91 (5.37-14.78)	<0.001
	35-64	41	3.93	8501.3	10.44 (7.69-14.18)	<0.001
	≥65	19	2.15	1647.4	8.84 (5.64-13.86)	<0.001
	Total	75	7.76	16706.2	9.67 (7.71-12.12)	<0.001
Group 4	<35	5	0.25	863.1	19.87 (8.27-47.73)	<0.001
	35-64	78	5.54	8628.0	14.07 (11.27-17.57)	<0.001
	≥65	123	19.80	8944.6	6.21 (5.21-7.41)	<0.001
	Total	206	25.59	18435.7	8.05 (7.02-9.23)	<0.001
Group 5	<35	0	0.20	675.0	0	<0.001
	35-64	86	21.84	33185.8	3.94 (3.19-4.86)	<0.001
	≥65	139	60.71	32609.4	2.29 (1.94-2.70)	<0.001
	Total	225	82.75	66470.2	2.72 (2.39-3.10)	<0.001
Group 6	<35	2	0.43	1705.0	4.62 (1.16-18.48)	0.030
	35-64	75	9.46	14202.3	7.92 (6.32-9.94)	<0.001
	≥65	95	28.74	13979.9	3.31 (2.70-4.04)	<0.001
	Total	172	38.63	29887.2	4.45 (3.83-5.17)	<0.001
Group 7	<35	32	1.44	7470.2	22.27 (15.75-31.49)	<0.001
	35-64	122	14.40	26056.1	8.47 (7.09-10.12)	<0.001
	≥65	189	40.66	21755.7	4.65 (4.03-5.36)	<0.001
	Total	343	56.50	55282.1	6.07 (5.46-6.75)	<0.001
Group 8	<35	38	10.95	36272.6	3.47 (2.53-4.77)	<0.001
	35-64	912	308.16	504621.9	2.96 (2.77-3.16)	<0.001
	≥65	637	367.35	218997.1	1.73 (1.60-1.87)	<0.001
	Total	1587	686.46	759891.6	2.31 (2.20-2.43)	<0.001
Group 8-1	<35	15	2.84	10598.4	5.29 (3.19-8.77)	<0.001
	35-64	308	31.59	53195.6	9.75 (8.72-10.9)	<0.001
	≥65	175	44.56	23298.2	3.93 (3.39-4.55)	<0.001
	Total	498	78.98	87092.1	6.31 (5.78-6.88)	<0.001

180 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation;
 181 Group 3: patients who used tumor necrosis factor inhibitors; Group 4: patients with end-stage renal disease; Group
 182 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with
 183 hematologic malignancy; Group 8: patients with diabetes mellitus; Group 8-1: patients with diabetes mellitus who
 184 needed regular insulin injection.
 185

186 TB: tuberculosis; SIR: standardized incidence ratio.

187

188 *Proportion of each cohort among nationwide TB cases*

189 Table 4 presents number of TB cases notified in 2018 among each cohort and proportion of
190 each cohort among 33,328 nationwide TB cases notified in 2018. Most of prevalence cohorts
191 accounted for less than 1.5% of total notified TB cases except for Group 8 (17.2%). The proportion of
192 each incidence cohort was similar to or lower than that of the prevalence cohort. Most of incidence
193 cohorts accounted for less than 1% of total notified TB cases except for Group 8 (3.3%).

195 Table 4. Number of TB cases notified in South Korea, 2018 among each cohort and proportion of
 196 each cohort among total nationwide TB cases notified in South Korea, 2018 (n = 33,328)

	TB cases among prevalence cohort, N (proportion %)	TB cases among incidence cohort ^a , N (proportion %)
All age (n=33,328)		
Group 1	48 (0.1)	50 (0.2)
Group 2	80 (0.2)	34 (0.1)
Group 3	79 (0.2)	26 (0.1)
Group 4	501 (1.5)	88 (0.3)
Group 5	480 (1.4)	89 (0.3)
Group 6	103 (0.3)	64 (0.2)
Group 7	144 (0.4)	158 (0.5)
Group 8	5724 (17.2)	1097 (3.3)
Group 8-1	2453 (7.4)	398 (1.2)
Total	6613 (19.8)	1572 (4.7)
Age <35 (n=4,155)		
Group 1	6 (0.1)	8 (0.2)
Group 2	3 (0.1)	4 (0.1)
Group 3	21 (0.5)	7 (0.2)
Group 4	6 (0.1)	2 (0.0)
Group 5	3 (0.1)	0 (0)
Group 6	2 (0.0)	1 (0.0)
Group 7	10 (0.2)	18 (0.4)
Group 8	38 (0.9)	24 (0.6)
Group 8-1	29 (0.7)	12 (0.3)
Total	84 (2.0)	58 (1.4)
Age 35-64 (n=13,916)		
Group 1	35 (0.3)	38 (0.3)
Group 2	61 (0.4)	26 (0.2)
Group 3	39 (0.3)	14 (0.1)
Group 4	203 (1.5)	37 (0.3)
Group 5	140 (1.0)	36 (0.3)
Group 6	37 (0.3)	26 (0.2)
Group 7	55 (0.4)	60 (0.4)
Group 8	2067 (14.9)	689 (5.0)
Group 8-1	987 (7.1)	258 (1.9)
Total	2411 (17.3)	913 (6.6)
Age ≥ 65 (n=15,257)		
Group 1	7 (0.0)	4 (0.0)
Group 2	16 (0.1)	4 (0.0)
Group 3	19 (0.1)	5 (0.0)
Group 4	292 (1.9)	49 (0.3)
Group 5	337 (2.2)	53 (0.3)
Group 6	64 (0.4)	37 (0.2)
Group 7	79 (0.5)	80 (0.5)
Group 8	3619 (23.7)	384 (2.5)
Group 8-1	1437 (9.4)	128 (0.8)
Total	4118 (27.0)	601 (3.9)

197 ^aOnly patients who were enrolled in 2018 were analyzed.
 198 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation;
 199 Group 3: patients who used tumor necrosis factor inhibitors; Group 4: patients with end-stage renal disease; Group
 200 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with
 201 hematologic malignancy; Group 8: patients with diabetes mellitus; Group 8-1: patients with diabetes mellitus who
 202 needed regular insulin injection.
 203 TB: tuberculosis.

204 Age-stratified proportion of each cohort was presented in Table 4. For high TB-risk diseases
205 (Group 1, 2, 3) and DM (Group 8) proportions of incidence cohort were highest among TB patients
206 aged between 35-64 years. For moderate TB-risk diseases such as ESRD (Group 4), or malignancy
207 (Group 5, 6, 7), those were highest among TB patients aged over 65 years. Proportions of each
208 incidence cohort were relatively low among TB patients aged under 35 years, in most of diseases.
209 However, those of high TB-risk disease (Group 1, 2, 3) among TB patient aged over 65 years were
210 even lower than among TB patients aged under 35 years.

211

212 *LTBI test uptake rate*

213 The uptake rate of LTBI test was the highest in Group 3, with 92.7% of patients in Group 3
214 undergoing LTBI test within a year before or after the initiation of TNF inhibitors (Table 5). The
215 percentage was 41.3% in Group 1 and 60.4% in Group 2. These percentages were lower in groups
216 with moderate TB risk diseases. Only 14.1% and 12.0% of patients in Group 4 and Group 7
217 underwent LTBI test recently or newly, respectively. These percentage for other moderate TB risk
218 groups were even lower. IGRA rather than TST was the mostly used LTBI test in each group.

219

220 Table 5. Percentage of patients who underwent latent TB screening with interferon-gamma release
 221 assay (IGRA) or tuberculin skin test (TST) for each incidence cohort.

(1) IGRA or TST				
	Recent or new screening (row %)	Past screening (row %)	No screening (row %)	Total
Group 1	1815 (41.3)	43 (1.0)	2542 (57.8)	4400
Group 2	7221 (60.4)	315 (2.6)	4429 (37.0)	11965
Group 3	8675 (92.7)	358 (3.8)	325 (3.5)	9358
Group 4	1558 (14.1)	155 (1.4)	9347 (84.5)	11060
Group 5	424 (1.2)	223 (0.6)	34807 (98.2)	35454
Group 6	393 (2.3)	207 (1.2)	16669 (96.5)	17269
Group 7	4235 (12.0)	490 (1.4)	30572 (86.6)	35297
Group 8	2103 (0.7)	231 (0.1)	304979 (99.2)	307313
Group 8-1	794 (2.1)	53 (0.1)	37386 (97.8)	38233
(2) IGRA				
	Recent or new IGRA (row %)	Past IGRA (row %)	No IGRA (row %)	Total
Group 1	1802 (41.0)	24 (0.5)	2574 (58.5)	4400
Group 2	7108 (59.4)	265 (2.2)	4592 (38.4)	11965
Group 3	8650 (92.4)	335 (3.6)	373 (4.0)	9358
Group 4	1551 (14.0)	91 (0.8)	9418 (85.2)	11060
Group 5	419 (1.2)	127 (0.4)	34908 (98.5)	35454
Group 6	390 (2.3)	111 (0.6)	16768 (97.1)	17269
Group 7	4193 (11.9)	294 (0.8)	30810 (87.3)	35297
Group 8	2067 (0.7)	196 (0.1)	305050 (99.3)	307313
Group 8-1	779 (2.0)	43 (0.1)	37411 (97.9)	38233
(3) TST				
	Recent or new TST (row %)	Past TST (row %)	No TST (row %)	Total
Group 1	56 (1.3)	37 (0.8)	4307 (97.9)	4400
Group 2	774 (6.5)	264 (2.2)	10927 (91.3)	11965
Group 3	919 (9.8)	478 (5.1)	7961 (85.1)	9358
Group 4	84 (0.8)	98 (0.9)	10878 (98.4)	11060
Group 5	15 (0.0)	112 (0.3)	35327 (99.6)	35454
Group 6	7 (0.0)	119 (0.7)	17143 (99.3)	17269
Group 7	127 (0.4)	270 (0.8)	34900 (98.9)	35297
Group 8	126 (0.0)	72 (0.0)	307115 (99.9)	307313
Group 8-1	63 (0.2)	23 (0.1)	38147 (99.8)	38233

222 Group 1: patients with human immunodeficiency virus; Group 2: patient who underwent organ transplantation;
 223 Group 3: patients who used tumor necrosis factor inhibitors; Group 4: patients with end-stage renal disease; Group
 224 5: patients who underwent gastrectomy; Group 6: patients with head & neck cancer; Group 7: patients with
 225 hematologic malignancy; Group 8: patients with diabetes mellitus; Group 8-1: patients with diabetes mellitus who
 226 needed regular insulin injection.
 227 IGRA: interferon-gamma release assay; TST: tuberculin skin test.

228 Recent screening denotes that latent TB examination (IGRA or TST) is performed within one year before the
229 date of enrollment. New screening indicates that the screening is performed at the date of enrollment or
230 thereafter. Past screening represents that the screening is performed more than one year before the date of
231 enrollment.
232

233 **DISCUSSION**

234 In this study, well-known high TB risk diseases showed high SIRs as expected. Patients with
235 ESRD showed TB risk comparable to those with high TB risk diseases. TB risk was relatively low in
236 patients who underwent gastrectomy and patients with DM among groups with moderate TB risk.
237 However, patients with uncontrolled DM status showed a relatively high TB risk. The uptake rate of
238 LTBI screening in these clinical risk group was still suboptimal in all groups except for patients who
239 used TNF inhibitors.

240 Previous LTBI guidelines did not specify when to treat in detail[5-8,15]. We demonstrated
241 that TB risk of patients who developed the disease newly was higher than that of those who were
242 diagnosed several years ago. This might be attributable to a decreased immunity of patients with an
243 uncontrolled status of disease around the date of diagnosis. Considering that in South Korea,
244 diagnosis rate of human immunodeficiency virus (HIV) was still suboptimal[16]. Many patients
245 presented low CD4+ cell levels at diagnosis[17], which might have increased their vulnerability to TB
246 at diagnosis as shown in a previous study[18]. Uncontrolled naïve DM and uremic status of patients
247 with chronic kidney disease (CKD) initiating dialysis might have also contributed to the high TB
248 incidence at diagnosis. Additionally, intensive immunosuppressive treatment following solid organ or
249 hematopoietic stem cell transplantation and consecutive use of TNF inhibitors could increase TB risk.
250 Among patients with malignancy, it was presumed that immunosuppressive states might be temporary
251 during a session of anticancer treatments such as chemotherapy just after the diagnosis of cancer,
252 which was demonstrated by decreasing SIR of TB with increasing time after cancer diagnosis[19].

253 Our findings underscored that LTBI screening should be focused on incident groups.
254 However, most of incident groups showed higher mortality as well as higher TB incidence than
255 prevalent groups. Among patients who were newly diagnosed as ESRD, 33.0% (3617/10977) of
256 patients died during the follow-up period. Considering adverse effects of LTBI treatment such as
257 gastrointestinal trouble and hepatotoxicity[20], we speculate that providing LTBI treatment to these
258 critically ill patients might be unfeasible in many cases. Moreover, in patients newly diagnosed as
259 malignancy, preventing TB would not be a medical priority. In a previous study, TB incidence was

260 higher among patients with malignancy such as esophageal, lung, pancreatic cancer, and multiple
261 myeloma, showing a relatively low 5-year survival[21]. We expect that the acceptance rate for LTBI
262 treatment among these patients with limited life expectancy would be low. Low LTBI screening
263 uptake rate in patients with malignancy (Groups 5, 6, 7) might be related to this reason.

264 However, Groups 2 and 3 showed relatively high uptake rates for LTBI screening (60.4%
265 and 92.7%, respectively). This might be because LTBI screening and treatment are more feasible in
266 these groups than in other groups. Mortality rate of Group 3 was the lowest among all incident groups.
267 This finding suggests that LTBI screening would be more feasible when they are scheduled to be a
268 high-risk group, than when they had already become. Relatively low uptake rate of LTBI screening
269 rate among PLHIV (41.3%) who were specified as the highest TB risk group could be explained by
270 this hypothesis considering a low diagnosis rate of HIV and a low CD4+ cell count at diagnosis
271 suggesting delayed diagnosis of HIV in South Korea[16,17]. We presume that diagnosis of HIV in
272 earlier course of the disease would enhance the LTBI screening uptake rate. Further studies are
273 needed to verify this hypothesis.

274 ESRD showed high SIR as other diseases with high TB risk, although it was specified as a
275 disease with moderate TB risk in South Korea[15]. Additionally, it showed the highest SIR among all
276 prevalent groups, suggesting that immunosuppression state could last for a longer period than other
277 groups. Therefore, it should be reclassified as a disease with a high TB risk. However, LTBI
278 screening is not widely performed for those with ESRD. We speculate that screening LTBI at earlier
279 stage in chronic kidney disease (CKD) could be an alternative option for increasing the uptake rate of
280 LTBI screening, like that for PLHIV. However, potential nephrotoxicity of anti-TB medication,
281 especially rifampicin, is a concern[22], which might lower the uptake rate of LTBI treatment among
282 patients with pre-dialysis CKD. LTBI regimen without potential risk of nephrotoxicity should be
283 investigated.

284 DM is a known risk factor for TB[23]. However, in our study, TB risk was relatively low
285 among diseases with moderate TB risk. Instead, uncontrolled DM status rather than disease itself
286 contributed to TB development, as reported in a previous study[24]. By focusing on patients with

287 uncontrolled DM, the cost of LTBI screening could be reduced while the effectiveness of TB
288 prevention is increased. However, mortality rate of this group was quite high – more than 10 times as
289 high as that of the total DM group. This suggests that there might be other serious comorbidities
290 among them. As in patients with ESRD and those with malignancy, comorbidities might limit the
291 feasibility of LTBI screening.

292 Besides feasibility, strategy targeting these clinical risk groups has other limitations. First,
293 these clinical risk groups accounted for only small proportion of nationwide TB patients – less than
294 1.5% for each group except for patients with DM. Similarly to our results, Ronald et al. have
295 demonstrated that application of WHO’s LTBI guideline targeting only for TB contacts and clinical
296 risk group can only minimally impact the national TB incidence of Canada[25]. Only 4.5% of active
297 TB cases were preventable with this strategy. This suggests that covering clinical risk group is
298 essential but insufficient to reduce TB burden. Identification of additional high-risk groups is
299 required[26]. Second, when compared to SIR in younger generation, SIR in elderly population was
300 much lower in most groups. This suggests that identifying diseases with a high TB risk could be a
301 useful tool for risk stratification among younger generation whereas it is less useful in elderly
302 population. The low SIR in elderly population is attributable to a high TB incidence among general
303 elderly population in South Korea[27]. Other comorbidities not specified in current guidelines,
304 waning immunity derived from aging, and malnutrition might also contribute to this[28]. In addition,
305 we demonstrated that proportions of high TB risk diseases among elderly TB patients were extremely
306 low, and lower than other age groups, implying LTBI screening strategy targeting for high TB risk
307 diseases is less efficient in elderly population, than in other age groups.

308 In the previous Canadian study, covering immigrants from high TB burden countries
309 potentially prevented 37.1% of total TB cases[25]. However, in South Korea, the proportion of
310 foreign-born residents among total population was 3.4% in 2020, which was lower than average
311 (14.7%) of other high-income countries[29]. Instead, native elderly TB patients are a key group in
312 South Korea. In 2021, TB patients who aged 65 years or above accounted for approximately 51.0% of
313 total TB cases[9]. LTBI screening and treatment among elderly population are not routinely

314 recommended due to low predictive values of diagnostic tools such as IGRA and TST and higher
315 incidence of adverse effects during LTBI treatment[20]. Recently, the necessity of expanding LTBI
316 screening to elderly population has been suggested[30] and the feasibility of LTBI treatment among
317 high-risk elderly population has been reported[31]. Further studies identifying high-risk elderly
318 population should be implemented.

319 This study has a strength of linking two databases covering the entire South Korean
320 population. Thus, many study subjects were included. We compared several diseases with high or
321 moderate TB risk simultaneously at nationwide level within the same study period. However, our
322 study had a limitation in that the LTBI status of each patient was unavailable. SIR among patients
323 with LTBI might reflect more accurate TB risk. However, considering that most diseases did not
324 affect LTBI prevalence[5] and that age was the most significant factor associated with LTBI
325 prevalence[32], we assumed that LTBI prevalence in each group and general population were not
326 quite different, and that age-adjusted SIR would be sufficient for estimating the actual TB risk.
327 Another limitation was that the number of patients with LTBI was not known. Thus, calculation of
328 further cascade of care such as initiation of LTBI treatment was unfeasible.

329 In conclusion, LTBI screening in certain clinical risk groups such as patients with ESRD and
330 patients with uncontrolled DM should be reinforced. Ideally, LTBI screening should be provided
331 around the date of the disease diagnosis. However, feasibility of LTBI treatment at that period
332 remains a problem. Beyond the current guideline, identification of additional high-risk groups,
333 especially among elderly population, is required.

334

335 **Financial Disclosure Statement**

336 This work was supported by a Research Program funded by Korea Disease Control and
337 Prevention Agency (<https://www.kdca.go.kr/>) (2020E310100 to JSK). The funders had no role in
338 study design, data collection and analysis, decision to publish, or preparation of the manuscript.

339

340 **Competing interests**

341 The authors have declared that no competing interests exist.

342 **References**

- 343 1. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-
344 estimation Using Mathematical Modelling. *PLOS Medicine*. 2016; 13:e1002152.
345 <https://doi.org/10.1371/journal.pmed.1002152>
- 346 2. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annu Rev*
347 *Public Health*. 2013; 34:271-286. <https://doi.org/10.1146/annurev-publhealth-031912-114431>
348 PMID: 23244049
- 349 3. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al.
350 Predictive value of interferon- γ release assays for incident active tuberculosis: a systematic
351 review and meta-analysis. *Lancet Infect Dis*. 2012; 12:45-55. [https://doi.org/10.1016/s1473-](https://doi.org/10.1016/s1473-3099(11)70210-9)
352 [3099\(11\)70210-9](https://doi.org/10.1016/s1473-3099(11)70210-9) PMID: 21846592
- 353 4. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with
354 *Mycobacterium tuberculosis*: update 2010. *Eur Respir J*. 2011; 37:690-711.
355 <https://doi.org/10.1183/09031936.00079310> PMID: 20693257
- 356 5. European Centre for Disease Prevention and Control. Programmatic management of latent
357 tuberculosis infection in the European Union; 2018 [cited 2023 25th Jan]. Available from:
358 [https://www.ecdc.europa.eu/en/publications-data/programmatic-management-latent-](https://www.ecdc.europa.eu/en/publications-data/programmatic-management-latent-tuberculosis-infection-european-union)
359 [tuberculosis-infection-european-union](https://www.ecdc.europa.eu/en/publications-data/programmatic-management-latent-tuberculosis-infection-european-union)
- 360 6. National Institute for Health and Care Excellence. Tuberculosis, NICE guideline; 2016 [cited
361 2023 25th Jan]. Available from: www.nice.org.uk/guidance/ng33
- 362 7. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1:
363 prevention: tuberculosis preventive treatment; 2020 [cited 2023 25th Jan]. Available from:
364 <https://www.who.int/publications/i/item/9789240001503>
- 365 8. Targeted tuberculin testing and treatment of latent tuberculosis infection. *Am J Respir Crit*
366 *Care Med*. 2000; 161:S221-247. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
367 PMID: 10764341

- 368 9. Korea Disease Control and Prevention Agency. Annual Report on the Notified Tuberculosis
369 in Korea, 2021. 2022.
- 370 10. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR, Jr. Estimated rate of
371 reactivation of latent tuberculosis infection in the United States, overall and by population
372 subgroup. *Am J Epidemiol.* 2014; 179:216-225. <https://doi.org/10.1093/aje/kwt246> PMID:
373 24142915
- 374 11. World Health Organization. Towards tuberculosis elimination: an action framework in low-
375 incidence countries. Geneva; 2014.
- 376 12. Go U, Park M, Kim U-N, Lee S, Han S, Lee J, et al. Tuberculosis prevention and care in
377 Korea: Evolution of policy and practice. *Journal of Clinical Tuberculosis and Other
378 Mycobacterial Diseases.* 2018; 11:28-36.
379 <https://doi.org/https://doi.org/10.1016/j.jctube.2018.04.006>
- 380 13. Organization for Economic Cooperation and Development. OECD Reviews of Public Health:
381 Korea. A Healthier Tomorrow; 2020. Available from: [https://www.oecd-
382 ilibrary.org/sites/6e005d47-en/index.html?itemId=/content/component/6e005d47-en](https://www.oecd-ilibrary.org/sites/6e005d47-en/index.html?itemId=/content/component/6e005d47-en)
- 383 14. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean Guidelines
384 for Tuberculosis, 2nd edition. Korea Centers for Disease Control and Prevention; 2014.
- 385 15. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean Guidelines
386 for Tuberculosis, 4th edition. Korea Centers for Disease Control and Prevention; 2020.
- 387 16. Lee E, Kim J, Lee JY, Bang JH. Estimation of the Number of HIV Infections and Time to
388 Diagnosis in the Korea. *J Korean Med Sci.* 2020; 35:e41.
389 <https://doi.org/10.3346/jkms.2020.35.e41> PMID: 32056401
- 390 17. Kim MJ, Chang HH, Kim SI, Kim YJ, Park DW, Kang C, et al. Trend of CD4+ Cell Counts
391 at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea
392 HIV/AIDS Cohort Study, 1992-2015. *Infect Chemother.* 2017; 49:101-108.
393 <https://doi.org/10.3947/ic.2017.49.2.101> PMID: 28608664
- 394 18. Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on

- 395 ART: a systematic review and meta-analysis. PeerJ. 2017; 5:e4165.
396 <https://doi.org/10.7717/peerj.4165> PMID: 29259846
- 397 19. Cheng MP, Abou Chakra CN, Yansouni CP, Clossen S, Shrier I, Menzies D, et al. Risk of
398 Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin
399 Infect Dis. 2017; 64:635-644. <https://doi.org/10.1093/cid/ciw838> PMID: 27986665
- 400 20. Campbell JR, Dowdy D, Schwartzman K. Treatment of latent infection to achieve
401 tuberculosis elimination in low-incidence countries. PLoS Med. 2019; 16:e1002824.
402 <https://doi.org/10.1371/journal.pmed.1002824> PMID: 31170161
- 403 21. Cheon J, Kim C, Park EJ, Ock M, Lee H, Ahn JJ, et al. Active tuberculosis risk associated
404 with malignancies: an 18-year retrospective cohort study in Korea. J Thorac Dis. 2020;
405 12:4950-4959. <https://doi.org/10.21037/jtd.2020.02.50> PMID: 33145069
- 406 22. Grilo Novais A, Silva C, Coelho AR, Silva R, Carvalho AC. Rifampicin-Induced
407 Nephrotoxicity in a Tuberculosis Patient: Treatment Dilemma? Eur J Case Rep Intern Med.
408 2021; 8:002833. https://doi.org/10.12890/2021_002833 PMID: 34790626
- 409 23. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic
410 review of 13 observational studies. PLoS Med. 2008; 5:e152.
411 <https://doi.org/10.1371/journal.pmed.0050152> PMID: 18630984
- 412 24. Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes Status and Association With
413 Risk of Tuberculosis Among Korean Adults. JAMA Netw Open. 2021; 4:e2126099.
414 <https://doi.org/10.1001/jamanetworkopen.2021.26099> PMID: 34546370
- 415 25. Ronald LA, Campbell JR, Rose C, Balshaw R, Romanowski K, Roth DZ, et al. Estimated
416 Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region
417 With a Low Tuberculosis Incidence: Retrospective Cohort Study. Clin Infect Dis. 2019;
418 69:2101-2108. <https://doi.org/10.1093/cid/ciz188> PMID: 30856258
- 419 26. Bigio J, Viscardi A, Gore G, Matteelli A, Sulis G. A scoping review on the risk of
420 tuberculosis in specific population groups: can we expand the World Health Organization
421 recommendations? Eur Respir Rev. 2023; 32 <https://doi.org/10.1183/16000617.0127-2022>

- 422 PMID: 36631131
- 423 27. Kim JH, Yim JJ. Achievements in and Challenges of Tuberculosis Control in South Korea.
424 Emerg Infect Dis. 2015; 21:1913-1920. <https://doi.org/10.3201/eid2111.141894> PMID:
425 26485188
- 426 28. Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the Elderly. J Clin
427 Med. 2021; 10 <https://doi.org/10.3390/jcm10245888> PMID: 34945187
- 428 29. United Nations Department of Economic and Social Affairs Population Division.
429 International Migrant Stock 2020. 2020.
- 430 30. Huynh GH, Klein DJ, Chin DP, Wagner BG, Eckhoff PA, Liu R, et al. Tuberculosis control
431 strategies to reach the 2035 global targets in China: the role of changing demographics and
432 reactivation disease. BMC Med. 2015; 13:88. <https://doi.org/10.1186/s12916-015-0341-4>
433 PMID: 25896465
- 434 31. Huang HL, Huang WC, Lin KD, Liu SS, Lee MR, Cheng MH, et al. Completion Rate and
435 Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly
436 Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. Clin
437 Infect Dis. 2021; 73:e1252-e1260. <https://doi.org/10.1093/cid/ciab209> PMID: 33677558
- 438 32. Kim HW, Min J, Choi JY, Shin AY, Myong JP, Lee Y, et al. Prevalence of latent tuberculosis
439 infection among participants of the national LTBI screening program in South Korea - A
440 problem of low coverage rate with current LTBI strategy. Front Public Health. 2022;
441 10:1066269. <https://doi.org/10.3389/fpubh.2022.1066269> PMID: 36743163